What’s Cabot Small-Cap Confidential’s “Stock of the Decade?”

WP Greet Box icon
Welcome! If you are new to Stock Gumshoe, grab a free membership here and join us to get our free newsletter alerts with new teaser answers and debunkings. Thanks!
Not new? Please log in at top right of this page

This note about a Cabot Small-Cap Confidential teaser first ran in the Friday File in the Summer of 2013, and the stock is up about 25% since then but is now being pitched as Cabot’s “Stock of the Decade”.

What follows was published on June 21, 2013 and has not been updated or revised:


I thought you might enjoy a quick look at a teaser ad for one of Thomas Garrity’s picks from Cabot Small-Cap Confidential — they’re promoting this pretty actively right now as a “$20 biotech stock to hit $48,” as their innovative medical device gets approval to treat a much larger number of patients.

So what is it? Here’s the tease:

“$20 Biotech Stock to Hit $48

“All thanks to its revolutionary medical devices system that already delivered 140% gains to date….

“This Could Be an Easier Double Than The 974% Gains We Made In Monster Beverage”

They describe their strategy/philosophy of stock-picking thusly:

“Here at Cabot Small-Cap Confidential, we have found that the secret to profitable investing is to invest in game-changing technologies that not only stand in the path of growth but revolutionize entire industries.

“The reasons these companies have been so lucrative for us is they (1) change the way an entire industry does business and (2) have proprietary technologies that right from the beginning give them such a monopoly-like market share that few competitors can ever catch up.”

And tell us that this gives you a chance to invest in stocks that might be the next Priceline.com, Netflix, or Apple, to name a few of the examples they throw out.

Then we start to get details:

“Just like Monster Beverage’s breakthrough natural drink products revolutionized the beverage industry, this small-cap medical juggernaut is doing the same thing for the treatment of heart disease.

“With heart disease the leading cause of death for both men and women, this is one medical stock on a growth trajectory that could easily surpass the big profits we made in Monster Beverage.

“What makes me say so?

“Because this company’s treatment for Peripheral Arterial Disease (PAD), which will affect one in 20 Americans in their lifetime, could make heart angioplasty obsolete.”

OK, so that’s a nice big market — what’s the technology that’s shaking things up, and that has already driven the shares of this stock to more than double, with more (so they say) to come?

“Unlike angioplasty, which uses a metal mesh to inflate and stretch traumatized arteries to clear arterial blockages, this company’s treatment is like using a plumber’s snake to unclog your drain.

“Just like a plumber’s snake, it also uses a spinning drill-bit to sand plaque from arterial walls. Without getting too technical, it does this in a way that significantly minimizes the rise of trauma and ischemia.

“Since the company received FDA clearance to market this product, its stock price has risen an incredible 116% while its revenues have increased 24% quarterly.

“Now that its arterial-cleaning solution has been proven for treating PAD, the company is in the final phases of having its arterial blocking products approved for treating Coronary Artery Disease (CAD), which is the most common form of heart disease and costs the United States more than $100 billion each year.”

Irregulars Quick Take
Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? log in at top right)
Doesn’t that sound just lovely? A plumber’s snake squirming around inside your arteries? Yeeks. And better yet, the trade name used to be the Diamondback, with “Viperwire” accessories. It seems like they’ve moved on to the next generation of the core product under the “Stealth 360” trade name (the stealth is electric, the diamondback was pneumatic), but this is basically a wire that goes into the vessel and has a small diamond-coated lump on it — very technical term, I know — that spins around in the artery to essentially sand away the plaque from artery walls, including hardened plaque that’s otherwise very difficult to remove with other treatments.

And yes, the company is Cardiovascular Systems, Inc (CSII). And they do have a device that’s being used — successfully, as far as I can tell — to treat Peripheral Arterial Disease (PAD), and has been for several years. The pneumatic Diamonback version was approved back in 2007 and the newer Stealth electric one in 2011, so this is not a brand new treatment. Revenue is continuing to grow thanks to the continuing adoption of the technology, more sales in more labs and hospitals that increase usage, but it’s only growing by perhaps 20% or so, year over year. That would be great for most companies, particularly if you have a nice fat gross margin like CSII does on their devices and accessories (75% or so gross profit from those sales) … but for a $500 million company that’s generating $20-30 million in revenue per quarter and spending more than that on their sales force rampup, administrative costs, and clinical studies for the expanded use of the device, it’s not enough.

So what investors are banking on, including those who ponied up to add more shares in the secondary offering they did to raise cash this Spring (at $17.50, FYI, it’s around $20 now), is that they will both continue this steady growth trend in sales for PAD treatments and get approval to market the device for the apparently much larger market of Coronary Artery Disease (CAD). From their last quarterly release indications seem to be that the trials are going well for this label expansion, and they’re still forecasting substantial investments in the sales force to ramp up for that new indication, but at this valuation I expect they’d be in trouble if they’re denied access to the CAD market. They say CAD approval would get them into a $1.5 billion market, so even a small piece of it would be meaningful for a company with annual sales of currently only $80 million or so … but without that, they’d have to make a financial decision.

The downside, financially, is that if they can’t get into CAD or other new markets and are just going to have to focus on taking more market share in PAD, a market where they’ve had a presence for six years now, then creating a cash flowing company from the current 15-20% annual revenue growth would mean essentially cutting the R&D budget at least in half and cutting probably 15% from their SG&A budget to break even. If they did that then there’s a reasonable chance for the growth to turn into profits. Even if they double revenue over a couple years, though, and keep a strong gross margin of, say, 80%, that would mean that even those cost-cutting moves would make it feasible to get profits of perhaps between $50-80 million. So if you did turn it into a green eyeshade operation and put an accountant in charge, there is a decent chance that the current price would be reasonable — a $500 million market cap and $50 million in growing annual profits would be fine.

The more likely downside, probably, would involve not losing CAD and slashing spending, but continuing to invest heavily in CAD expansion and into their sales force and just never seeing enough revenue growth to justify that — that would probably give the stock a long, slow withering with occasional spurts of excitement as clinical data or sales give investors fits of optimism or pessimism.

I don’t know which of those downsides is more likely, and obviously there are other possibilities that would be worse (like adverse reactions or accidents pulling the device from the market), but the upside is pretty compelling if they do get the expected label expansion — and it’s a unique, niche product that’s pretty easy to understand and follow, even if you’re not a medical expert, so if you’re looking for clinical trial-based upside stocks that have at least some established revenue and a possible pathway to profitability, you could certainly do a lot worse. I haven’t ever bought this one and I haven’t studied the market for the device or their trial data in any detail, but their existing revenues mean they have pretty substantial leverage to any potential growth — it wouldn’t take huge revenue increases to become profitable as long as they’re disciplined about their marketing costs.

And as with most single-product medical stocks, it’s much more of an individual story that impacts the shares — not the overall market or the European debt crisis or interest rate panic from the Fed watchers, so that’s always nice in a week like this. The potential revenue is substantial, given that they’re addressing a challenging disease (or pair of diseases, now) that are growing in importance as the demographic waves mean the U.S. population of people who are in their prime heart-trouble years continues to swell.

I haven’t bought CSII, but it does look like an intriguing story speculation from the Cabot folks — not sure how long it will be before news of the FDA’s response to their application for CAD approval will hit, since they got approval for a multi-step atypical application process that started in late 2012 with the initial submissions of data , but the review timeline is generally six months from submission so I expect we’ll probably see something definitive before the end of the year, possibly significantly sooner. I think most investors are probably expecting approval, so that might mute any “pop” from approval, probably depending on how fast they think they can build that business, but I imagine a rejection would be instantly very negative for the shares.

Email This Email This

17 Responses to What’s Cabot Small-Cap Confidential’s “Stock of the Decade?”

  1. Speaking of medical, I’m currently up a bit over 160% on CLDX and from my DD has a long way to go… Several products in the pipe that could take it a long way…


  2. Hi Travis. A toll-bridge stock? Now THAT interests me. If you all don’t mind me changing the subject , Charles Mizrahi has teased about a royalty stock that offers a nice payout to owners of the stock on every smart phone sold. EVERY. Must be a very vital cihip. This appeared in his recent Hidden Values Alert. Would you please put on your famous Thinkolator and reveal the stock to your followers? Thanks, in advance. Marilyn


  3. another company in PAD business and also in other medical devices (and the hot business of supplying replacement parts for them) is Covidien, an Irish firm we tip, COV on the Big Board, which just spun off is pharma arm called Mallinckrodt. It is not my idea but one from a CFA contributor, Murray Lansdown. It’s doing okay but with the spinoff is hard to value. I think it is going higher and is less risky than CSII while also focusing on arterial cleaning because it does other stuff too.


  4. Speaking of biotech stocks, for me the best investment is BB Biotech, pleas have a look!
    NAV 165 CHF, shars 125,40 CHF, divid. 4.50 CHF super managment! You will never have a better diversivication of biotech stocks with a great discount!
    For al infos go to: bbbiotech.ch
    (sorry about my english)


  5. For a spec, take a look at a company that combines the new 3D technology with bioscience: Organovo Holdings (ONVO) which just listed their shares on the NY stock exchange this week. They are in the formative stages but I am impressed with the credentials of the new Board Member… a lady recently appointed who is a mover and shaker.


  6. Many thanks to Tanglewood. I really appreciate your info and web address for the company. Qualcomm sounds very interesting, though expensive. I guess you get what you pay for. Will try it. Double thanks. You are all so helpful. Marilyn


  7. INO (Inovio) has just published a mouse study using its electroporation vaccination procedure to achieve significant improvement in PAD by inducing blood vessel growth. You might note, also, that this company has shown protective vaccination against H7N9, the flu virus spreading in China, as well as, H5N1 the slow spreading bird flu.


  8. Speaking of biotech stocks on the move .. a few weeks ago I watched a teaser featuring a company in the business of framing a sea animal, the Giant Keyhole Limpet. Now, stop laughing! This animal is critical in supplying the Pharma industry a little produc called KLH. It is derived from the Limpets blood. Problem is, when you draw the blood, the animal dies. And, there are only an estimated 100K of these critters left worldwide – they are found in one place only, a little section of Pacific ocean just off the coast of Ventura County, CA. The Pharmas cannot conduct many of their required trials without KLH. Remove that and you have a great reduction in R&D on new cancer drugs and other like critical things. I took what the tease showed of the plant this company has developed to “farm” the Limpets, the many patents it already has on a process of getting tem to reproduce in captivity, how to draw blood without kiling the thing, etc., and found it to be called Stellar Biotechnologies, Inc. it trades on the pinks under SBOTF.PK. Get htis: when I found it, it was trading for 0.73, up from 0.17 a year earlier. It was just bouncing around between 0.70 and 0.76 so I felt no rush while I continued to investigate it, especially how close they actually were in getting some Phase II clinical trials successfully completed which I felt should give it a life to some degree if and when accomplished. Then last Tuesday came around (July 16) and it popped from 0.73 to 0.83! But no news to justify. So I told myself it would correct on Wednesday. Nope – wrong again. It popped another 0.08 up to 0.91. Still no news. Figuring I would personally stop this rally, I bought in at 0.91 on Thursday PM. Told the trader to go short it because that is the effect I seem to always have on a runner. Friday opened and I was afraid to look. But I did. It was trading at 1.03!! Still no news. it closed right there. Does ANYBODY have any input as to why this sudden and large upside move is happening? I olny bought 7250 shares and want more – a LOT more – if this is for real. But I need info to make an informed decision, so I reach out. Anybody? Anybody? Also, quick comment on the company making these new P.A.D. artery scrapers .. I have P.A.D. – bad. Lost my left leg to it 5 years back, the right one very damaged to the point I can’t walk with a prosthesis. I can assure you, if this equipment is effective (and I plan to ask my vascular surgeon about it soon) it will be greeted by us folks with the affiction with open arms and wide open wallets. Inseting the stents like I had done is very painful, very time intensive in recovery, and not always very effective. Plus, you know they will eventually wear out and have to be replaced. Which risks losing the leg entirely. So I say, go for it! I’m going to have a long, hard, and very personal investigation of CSII for myself with an eye to investment profits AND a health care remedy.


    • I wrote about that KLH teaser pitch back in May here: http://stockgumshoe.com/reviews/alternative-energy-speculator/minting-millions-from-the-magic-molecule-nick-hodge/ — do be careful, this is almost entirely driven by Hodge at the moment and by the many readers he “turned on” to the story, there was essentially no volume in the stock before his recommendation. Investors often dramatically underestimate how much power a publisher with a few thousand subscribers can have over the short-term movements of a tiny, tiny stock, KLH was under $50 million before he started touting it and traded often less than $100,000 worth of shares in a day. The volume is much higher now, up to $700,000 a day recently, but even that is low enough for extreme volatility.

      The danger for these tiny story stocks that are driven by one big newsletter teaser campaign or recommendation is that they can fall very hard if that attention from the newsletter dries up — they don’t even have to recommend a “sell” on the stock, they can just ignore it and not promote that idea for a few months and it may fall … assuming that there isn’t big fundamental news from the company, of course, which is always possible.


  9. Looks like CSII has become more viable, with recent FDA approvals.
    12/3/13: CSIItoday announced that its new Diamondback 360® Coronary Orbital Atherectomy System (OAS) is being used by physicians across the country to treat coronary artery disease. This follows the company’s recent PMA approval from the U.S. Food and Drug Administration (FDA) to market the device as a treatment for severely calcified coronary arteries.


  10. As an add-on to post #1, I’m up over 240%, and I also think CLDX has a long way to go… Absolutely great pipeline…


Leave a Reply

Your email address will not be published. Required fields are marked *

What These Icons Mean

  • The user who posted this comment is a Stock Gumshoe Premium Member (also known as an "IRREGULAR").
  • This user regularly writes articles for Stock Gumshoe. They may or may not be the author of the current article.
  • This user's comments have been "liked” by at least a few members of the Stock Gumshoe community.
  • This user has commented widely, with input that has been liked enough to earn a two-thumbs-up rating from other readers.
  • This is the highest rating a user can get. They are among the most respected commentors of our community.